查看文章

BACKGROUND

The co-formulation of dolutegravir (DGV) with abacavir and lamivudine in a single pill under the brand name Triumeq® constitute the only complete single-tablet regimen (STR) preferred for the initiation of antiretroviral treatment (ART) in every national and international guidelines. The co-formulation of elvitegravir (EVG) with cobicistat, emtricitabine and tenofovir-alafenamide branded Genvoya® is preferred in the EACS and in the US-DHHS guidelines, and it is considered a first-line alternative in most other international and national guidelines. Both combinations have shown high levels both of efficacy and tolerability in their pivotal trials. In addition, the convenience of the STR, only shared by the otherwise less preferred co-formulations of rilpivirine and efavirenz, have favored their widespread use. However, of the 3 integrase strand transfer inhibitors (INSTI) approved by the European Medicines …